Cerebras Systems priced its IPO above $160 per share on Wednesday night, clearing the top of its raised range and valuing the AI chipmaker at close to $49 billion on a fully diluted basis. [1] The offering was oversubscribed more than 20 times. The stock begins trading Thursday on Nasdaq under the ticker CBRS.

The demand story is the one that will fill the business pages Thursday morning. The concentration story is the one buried in the S-1.

As the paper's May 12 account of Cerebras's raised price range laid out, this IPO was always a test of whether AI scarcity can be sold to public investors before the first trade. Wednesday's pricing is a data point in that test. Investors, apparently, believe it can. What they priced above $160 a share includes a risk profile that general coverage has underweighted.

The Concentration Map

In 2025, 86% of Cerebras's total revenue came from two related entities in the United Arab Emirates: the Mohamed bin Zayed University of Artificial Intelligence (MBZUAI) at 62% of revenue, and Group 42 (G42) at 24%. [2] These are not abstract risks. MBZUAI is an Abu Dhabi government institution. G42, the Abu Dhabi-based AI conglomerate, has US national security equities attached to it — it has navigated scrutiny from the Committee on Foreign Investment in the United States over its ties to Chinese technology companies.

Cerebras generated approximately $510 million in 2025 revenue, up from $290 million in 2024. Nearly all of that growth came from Abu Dhabi. The company's US customer base, and its European customer base, are marginal.

The IPO proceeds — up to $4.8 billion at the top of the raised range — are meant in part to diversify that customer base. The question public market investors are being asked to answer is whether that diversification is achievable within a timeframe that makes the current valuation rational.

The OpenAI Knot

The second structural concentration in the S-1 is the one that landed on the front pages last week: the Master Relationship Agreement with OpenAI, valued at over $20 billion. Under the MRA, OpenAI is obligated to purchase 750 megawatts of Cerebras AI inference compute capacity, with an option to expand to 2 gigawatts by 2030. [3]

In connection with a $1 billion advance from OpenAI, Cerebras issued warrants covering approximately 33 million non-voting shares at a near-zero strike price — vesting as OpenAI actually purchases compute capacity, with full vesting contingent on the full 2-gigawatt deployment. [4]

The governance implication is clean and uncomfortable: OpenAI is simultaneously Cerebras's largest future customer, a creditor with warrant rights, and a company whose own governance is currently being contested in federal court. Altman's testimony in the Musk trial concluded Wednesday; closing arguments are Thursday morning. The trial's outcome changes nothing about the MRA's contractual structure — but it changes the frame around the counterparty risk embedded in every Cerebras warrant.

Investors pricing Cerebras above $160 are, among other things, making a bet on OpenAI's continued operation under its current structure and scale. That is not a negligible assumption this week.

What the Demand Signal Tells Us

The 20x oversubscription tells you several things. It tells you that institutional appetite for AI infrastructure exposure is not exhausted, despite the concentration risks in the S-1. It tells you that the $150–$160 range established Monday was still below where demand cleared. It tells you that the story Cerebras told — wafer-scale silicon, direct competition with Nvidia's fragmented ecosystem — found buyers.

What it does not tell you is whether the buyers read the concentration map carefully. In a 20x oversubscribed book, the allocation dynamic means that most of the investors who wanted shares at $160 will get far fewer than they wanted. The aftermarket will be the first real test of whether the demand was structural or momentum-chasing.

The IPO is the largest anywhere in the world by size year-to-date, according to Dealogic data. [5] That superlative will be in every headline Thursday. The G42 revenue share will be in fewer of them.

-- THEO KAPLAN, San Francisco